A pilot study investigating the effect of Caralluma fimbriata extract on the risk factors of metabolic syndrome in overweight and obese subjects: A randomised controlled clinical trial

Complementary Therapies in Medicine

Volumn 21, Issue 3, 2013, Pages 180-189

  Astell, Katie J ^a   Mathai, Michael L ^a   McAinch, Andrew J ^a   Stathis, Christos G ^a   Su, Xiao Q ^a  

^a VICTORIA UNIVERSITY   (Australia)

Author keywords

Anthropometry; Appetite; Caralluma fimbriata; Central obesity; Lipid profile; Metabolic risk factors

Indexed keywords

ANOREXIGENIC AGENT; CARALLUMA FIMBRIATA EXTRACT; PLACEBO; PLANT EXTRACT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; APOCYNACEAE; ARTICLE; BODY MASS; CARALLUMA FIMBRIATA; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FAT INTAKE; FEMALE; HEART RATE; HIP CIRCUMFERENCE; HUMAN; MALE; METABOLIC SYNDROME X; OBESITY; PALATABILITY; PHYSICAL ACTIVITY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SODIUM INTAKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION;

ADULT; APPETITE; APPETITE DEPRESSANTS; ASCLEPIADACEAE; BODY MASS INDEX; BODY WEIGHT; DIET; FEMALE; HEMODYNAMICS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; PHYTOTHERAPY; PILOT PROJECTS; PLANT EXTRACTS; RISK FACTORS; TRIGLYCERIDES; WAIST CIRCUMFERENCE; WAIST-HIP RATIO;

EID: 84877131060     PISSN: 09652299     EISSN: 18736963     Source Type: Journal    
DOI: 10.1016/j.ctim.2013.01.004     Document Type: Article

References (37)

1. The National Cholesterol Education Program Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of American Medical Association 2001, 285(19):2486-2497.
2. Carr D.B., et al. Intra-abdominal fat is a major determinant of the national cholesterol education program adult treatment panel III criteria for the metabolic syndrome. Diabetes 2004, 53(8):2087-2094.
3. Yun J.E., et al. Serum leptin is associated with metabolic syndrome in obese and nonobese Korean populations. Metabolism 2010, 59(3):424-429.
4. Yatagai T., et al. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 2003, 52(10):1274-1278.
5. Giltay E.J., et al. Visceral fat accumulation is an important determinant of PAI-1 levels in young, nonobese men and women: modulation by cross-sex hormone administration. Arteriosclerosis, Thrombosis, and Vascular Biology 1998, 18(11):1716-1722.
6. van Harmelen V., et al. Increased lipolysis and decreased leptin production by human omental as compared with subcutaneous preadipocytes. Diabetes 2002, 51(7):2029-2036.
7. Abate N., et al. Relationships of generalized and regional adiposity to insulin sensitivity in men. Journal of Clinical Investigation 1995, 96(1):88-98.
8. Grant R.W., Meigs J.B. Management of the metabolic syndrome. Panminerva Medica 2005, 47(4):219-228.
9. Celleno L., et al. A Dietary supplement containing standardized Phaseolus vulgaris extract influences body composition of overweight men and women. International Journal of Medical Science 2007, 4(1):45-52.
10. Kuriyan R., et al. Effect of Caralluma fimbriata extract on appetite, food intake and anthropometry in adult Indian men and women. Appetite 2007, 48(3):338-344.
11. Kunert O., et al. Pregnane glycosides from Caralluma adscendens var. fimbriata. Chemistry & Biodiversity 2008, 5(2):239-250.
12. Gardiner J.V., et al. AAV mediated expression of anti-sense neuropeptide Y cRNA in the arcuate nucleus of rats results in decreased weight gain and food intake. Biochemical and Biophysical Research Communications 2005, 327(4):1088-1093.
13. Lawrence R., Choudhary S. Caralluma fimbriata in the treatment of obesity. The proceedings of the 12th annual world congress of anti-aging medicine 2004.
14. Academy of Nutrition and Dietetics Adult weight management evidence-based nutrition practice guideline. Executive Summary of recommendations 2010, Available from:. http://www.eatright.org/.
15. Australian Government Food for health. Dietary guidelines for Australians: a guide to healthy eating 2005, Department of Health and Ageing. National Health and Medical Research Council (Ed.).
16. Xyris Software Pty Ltd Food works professional 2007, Highgate Hill, Queensland, Australia.
17. Lohman T., Martorell R., Roche A. Anthropometric standardization reference manual 1988, Human Kinetics Publishers, United States.
18. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972, 18(6):499-502.
19. Drapeau V., et al. Appetite sensations as a marker of overall intake. British Journal of Nutrition 2005, 93(2):273-280.
20. Cameron A.J., et al. The metabolic syndrome in Australia: prevalence using four definitions. Diabetes Research and Clinical Practice 2007, 77(3):471-478.
21. Akbarsha M., et al. Effect of Caralluma Fimbriata extract on 3T3-L1 pre-adipocyte cell division. Science Research 2010, 2:329-336.
22. De Leo M., et al. New pregnane glycosides from Caralluma dalzielii. Steroids 2005, 70(9):573-585.
23. Plaza A., et al. New unusual pregnane glycosides with antiproliferative activity from Solenostemma argel. Steroids 2005, 70(9):594-603.
24. Cioffi G., et al. Pregnane glycosides from Leptadenia pyrotechnica. Journal of Natural Products 2006, 69(4):625-635.
25. Kamalakkannan S., et al. Antiobesogenic and antiatherosclerotic properties of Caralluma fimbriata extract. Journal of Nutrition and Metabolism 2010, 2010:285301.
26. Rocha P.M., et al. Independent and opposite associations of hip and waist circumference with metabolic syndrome components and with inflammatory and atherothrombotic risk factors in overweight and obese women. Metabolism 2008, 57(10):1315-1322.
27. Seidell J.C., et al. Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec family study. American Journal of Clinical Nutrition 2001, 74(3):315-321.
28. Snijder M.B., et al. Independent association of hip circumference with metabolic profile in different ethnic groups. Obesity Research 2004, 12(9):1370-1374.
29. Snijder M.B., et al. Independent and opposite associations of waist and hip circumferences with diabetes, hypertension and dyslipidemia: the AusDiab study. International Journal of Obesity and Related Metabolic Disorders 2004, 28(3):402-409.
30. Santos A.C., Ebrahim S., Barros H. Alcohol intake, smoking, sleeping hours, physical activity and the metabolic syndrome. Preventive Medicine 2007, 44(4):328-334.
31. Pratley R.E., et al. Aerobic exercise training-induced reductions in abdominal fat and glucose-stimulated insulin responses in middle-aged and older men. Journal of the American Geriatrics Society 2000, 48(9):1055-1061.
32. Stewart K.J. Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. Journal of American Medical Association 2002, 288(13):1622-1631.
33. Lutsey P.L., Steffen L.M., Stevens J. Dietary intake and the development of the metabolic syndrome: the atherosclerosis risk in communities study. Circulation 2008, 117(6):754-761.
34. Yuliana N.D., et al. Comprehensive review on herbal medicine for energy intake suppression. Obesity Reviews 2011, 12(7):499-514.
35. Thongpradichote S., et al. Identification of opioid receptor subtypes in antinociceptive actions of supraspinally-administered mitragynine in mice. Life Sciences 1998, 62(16):1371-1378.
36. Grundy S.M., et al. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 2005, 112(17):2735-2752.
37. Whelton P.K. Primary prevention of hypertension: rationale, approaches, realities and perspectives. Journal of Human Hypertension 1996, 10(Suppl. 1):S47-S50.